Accessibility Menu
Insight Molecular Diagnostics logo

Insight Molecular Diagnostics(NASDAQ) IMDX

Market Cap$150.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-96%
5 Year-95%
1 Year+85%
1 Month-18%
$4.65
+1.09%
+0.05Today
After hours$4.67+$0.02 (+0.43%)
Insight Molecular Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 4.652026-07-31
Insight Molecular Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.9%USD 4.742026-07-24
1 month-18.28%USD 5.692026-07-01
3 month+11.24%USD 4.182026-05-01
Year to date-38%USD 7.502025-12-31
1 year+84.52%USD 2.522025-07-31
3 year+12.59%USD 4.132023-08-01
5 year-95.48%USD 102.802021-07-30
Since inception-96.32%USD 125.002015-12-31

Insight Molecular Diagnostics Financials at a Glance

Market Cap

$150.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.95M

Net Income (TTM)

-$47.84M

EPS (TTM)

-$1.48

P/E Ratio

-3.14

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Price

$4.65

Volume

61,613.844

Open

$4.60

Previous Close

$4.65

Daily Range

$4.45 - $4.71

52-Week Range

$2.33 - $8.51

Estimated Earnings Date

Aug 10, 2026

IMDX News

Closeup of IV drip

Why Oncocyte Shot 13% Higher Today

Eric VolkmanFeb 5, 2021
stock-reversing-course

Here's Why OncoCyte Is Giving Back Some Gains Today

Cory RenauerJan 30, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Insight Molecular Diagnostics

Insight Molecular Diagnostics makes tests to help doctors find cancer. These tests also show if a new organ is being rejected. They help patients get the right medical treatment faster.

What’s Inside the Lab?

  • Laboratory Services: Specialized testing for drug companies including biomarker discovery and clinical trial support; accounted for 100% of revenue in Q1 2026.
  • Organ Transplant Tests: Tools like GraftAssureIQ measure specific markers to check if a body accepts a new organ.
  • Oncology Therapy Selection: Tests such as DetermaIO analyze gene expressions to help doctors choose cancer treatments.
  • Oncology Therapy Monitoring: Tracking solutions designed to monitor how well cancer treatments work over time.

Recent Moves and Big Partnerships

  • Formed a global strategic partnership with Bio-Rad Laboratories, Inc. in April 2024 to develop and sell transplant products.
  • Sold a 70% stake in Razor Genomics, Inc. to Dragon Scientific, LLC in February 2023 to reduce operational costs.
  • Relocated headquarters and clinical laboratory operations to Nashville, Tennessee in June 2025.
  • Raised $24.6 million in net proceeds through a registered stock offering in February 2026.

What Sets the Company Apart

Insight Molecular Diagnostics develops test kits that local hospitals can run in their own labs. The company also runs a federally certified clinical facility in Tennessee to support its research and development.

The Latest Financial Scorecard

  • Revenue was $32,000 in Q1 2026, down 98.5% from $2.1 million in Q1 2025.
  • Net loss narrowed to $4.3 million in Q1 2026, a 35.7% improvement from the $6.7 million loss in Q1 2025.
  • Free cash flow was negative $7.6 million in Q1 2026, which deepened 23.9% from the previous year.
  • Cash and cash equivalents reached $28.2 million as of March 31, 2026.

The Big Picture

Insight Molecular Diagnostics is moving its focus from cancer testing to the organ transplant market through new partnerships and internal restructuring. By relocating operations and selling certain assets, the company has streamlined its path toward selling diagnostic kits directly to laboratories.

AI Generated • May 15, 2026

Industry

Biotechnology

Sector

Health Care

Employees

58

CEO

Joshua Riggs

Website

www.oncocyte.com

Headquarters

Nashville, TN 37217, US

IMDX Financials

Key Financial Metrics (TTM)

Gross Margin

19.47%

Operating Margin

-2112.42%

Net Income Margin

-2454.64%

Return on Equity

380.80%

Return on Capital

N/A

Return on Assets

-118.34%

Earnings Yield

-31.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$150.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

32.29M

Volume

61.61K

Avg. Volume

298.23K

Financials (TTM)

Gross Profit

$379.50K

Operating Income

-$41.17M

EBITDA

-$45.40M

Operating Cash Flow

-$23.97M

Capital Expenditure

-$3.49M

Free Cash Flow

-$27.46M

Cash & ST Invst.

$28.20M

Total Debt

$3.07M

Insight Molecular Diagnostics Performance Analysis

Insight Molecular Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 958,000-56.4%
20232023-12-31USD 1,503,00056.9%
20242024-12-31USD 1,881,00025.1%
20252025-12-31USD 4,055,000115.6%
Insight Molecular Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-75.8%
Q32025-09-30-49.8%
Q42025-12-31338.1%
Q12026-03-31-97.2%
Insight Molecular Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.25-8.1%
20232023-12-31USD -3.75-71.7%
20242024-12-31USD -4.6624.2%
20252025-12-31USD -1.65-64.6%
Insight Molecular Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-17.2%
Q32025-09-30-11.8%
Q42025-12-31-120.6%
Q12026-03-3184.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$32.00K

-98.5%

Gross Profit

-$605.50K

-145.7%

Gross Margin

-18.92%

N/A

Market Cap

$150.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.59M

N/A

Employees

58

N/A

Net Income

-$4.29M

+35.7%

EBITDA

-$3.64M

+40.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$28.20M

-9.1%

Total Debt

$3.07M

-11.8%

Accounts Receivable

$157.00K

-95.6%

Inventory

$382.00K

-16.8%

Long Term Debt

$1.31M

-37.0%

Short Term Debt

$1.76M

+25.5%

Return on Assets

-1.18%

N/A

Return on Invested Capital

-1.45%

N/A

Free Cash Flow

-$8.25M

-33.9%

Operating Cash Flow

-$7.64M

-30.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IVVDInvivyd, Inc.
$0.54-8.01%
CDXSCodexis, Inc.
$1.40-5.41%
PEPGPepGen Inc.
$1.76-1.12%
MISTMilestone Pharmaceuticals Inc.
$1.11-3.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About IMDX

What is the current price of Insight Molecular Diagnostics?

Insight Molecular Diagnostics is trading at $4.65 per share.

What is the 52-week range for Insight Molecular Diagnostics?

Over the past 52 weeks, Insight Molecular Diagnostics has traded between $2.33 and $8.51.

How much debt does Insight Molecular Diagnostics have?

As of the most recent reporting period, Insight Molecular Diagnostics reported total debt of $3.07M.

How much cash does Insight Molecular Diagnostics have on hand?

Insight Molecular Diagnostics reported $28.93M in cash and cash equivalents in its most recent financial results.

What is Insight Molecular Diagnostics’s dividend yield?

Insight Molecular Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services